HEMS MEDICATION SECTION OCTREOTIDE (INTERFACILITY TRANSFER)

Date: December 9, 2021 Section: 9-50

Octreotide Interfacility Transfer

Indications:

Interfacility transport of a patient with Upper GI tract bleeding from esophageal varices that the Octreotide IV is initiated at the transferring facility and may be continued during transport by an ALS unit staffed with a Paramedic current with Expanded Scope of Practice training. This treatment is not to be initiated by the Expanded Scope of Practice Trained paramedic independently.

Contraindications:

Sensitivity to octreotide

Typical Sending Facility Administration:

Initial 50 mcg IV bolus, then 50 mcg/hr IV continuously

Procedure:

Maintain appropriate delivery rate by IV infusion pump.

Continuous cardiac monitoring, monitor vital signs every 10 minutes.

Adverse Effects:

Bradycardia, arrhythmias, hypertension

If patient develops bradycardia or cardiac arrhythmia, contact medical control from sending facility.

**Not in Medication Box

MCA Name: HEMS, Inc. (WW/DR) MCA Board Approval Date: 2/8/2024 MCA Implementation Date: 3/1/2024

MDHHS Approval: